This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376–1383
Lee WR et al. (1997) Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15: 230–238
Sandler HM et al. (2000) Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48: 629–633
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Glossary
- GLEASON SCORE
-
Sum of grades assigned to the two largest cancerous areas of tissue samples; grades range from 1 (least aggressive) to 5 (most aggressive) and the resultant score ranges from 2 (lowest) to 10 (highest)
Rights and permissions
About this article
Cite this article
Lee, W. What variables predict for metastasis in men with biochemical relapse following radiotherapy for prostate cancer?. Nat Rev Clin Oncol 2, 340–341 (2005). https://doi.org/10.1038/ncponc0223
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0223
This article is cited by
-
Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?
Nature Clinical Practice Oncology (2006)